巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Biodesix

    BDSX
    1.420
    0.180
    14.06%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Biodesix - 延遲價格・最後更新於 28/09 8:57
    最高位
    1.450
    最低位
    1.270
    開市價
    --
    前收市價
    1.245
    成交量(千)
    5.16
    成交額(百萬)
    0.06
    買入
    1.020
    賣出
    1.700
    每手股數
    --
    市值(百萬)
    56.77
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    8.750 - 1.225
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Biodesix
    證券代碼
    BDSX.US
    所屬板塊
    Diagnostics & Research
    公司業務
    Biodesix Inc is a data-driven diagnostic solutions company. Its artificial intelligence-based platform helps to discover, develop, and commercialize solutions for clinical unmet needs, with a focus on lung disease. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.
    發行量
    31307853
    公司總部
    2970 Wilderness Place, Suite 100
    公司網址
    https://www.biodesix.com
    公司電郵
    robin.cowie@biodesix.com
    公司電話
    +1 303 417-0500
    暫無內容

    關於

    Biodesix(BDSX.US)所屬的行業板塊為Diagnostics & Research。
    Biodesix Inc is a data-driven diagnostic solutions company. Its artificial intelligence-based platform helps to discover, develop, and commercialize solutions for clinical unmet needs, with a focus on lung disease. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.
    詳細公司背景可參考: https://www.biodesix.com